Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Capricor Therapeutics Inc ( NASDAQ:CAPR ) is nearing a major milestone with the upcoming top-line readout from their HOPE 3, phase 3 clinical study of Daremiah cell for Duchenne muscular dystrophy. The HOPE 3 trial is one of the largest double-blind placebo-controlled studies in the Duchenne population, enrolling 105 participants across 20 centers in the U.S. No new or emerging safety signals have been observed in the trial, maintaining a strong safety profile for Daremiah cell. Capricor Therapeutics Inc ( NASDAQ:CAPR ) has a solid cash position of approximately $98.6 million, expected to cover expenses into the fourth quarter of 2026. The company is eligible for an $80 million milestone payment and a priority review voucher if Daremiah cell is approved, providing significant non-dilutive capital opportunities. Negative Points Revenue for the third quart
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline DataGlobeNewswire
- Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CAPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]Seeking Alpha
- Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- CAPR's page on the SEC website